OAKLAND, N.J.—Ocumetra, a company offering data-powered communication and clinical support tools, has announced an investment and strategic partnership with Topcon Healthcare, Inc., a robotic medical devices and digital health care solutions company. By uniting Ocumetra’s myopia management platform with Topcon Healthcare’s cloud-based Harmony digital health platform, the company indicated that it is aiming to ensure eyecare providers can access and utilize myopia clinical support solutions at scale. “At Ocumetra, our mission is to deliver precise, patient-centered myopia management solutions that support the evolving needs of eyecare professionals and the patients they serve," said James Loughman, CEO of Ocumetra.

"We believe in better eye health for children and value strong partnerships built on trust, integrity, transparency, and authenticity to drive our ambition for positive global impact. This partnership with Topcon Healthcare, Inc., a company dedicated to transforming health care through a cloud-based platform and ecosystem, is a pivotal step toward realizing our vision for the future of myopia care. With great partners come great possibilities, and together, we are poised to transform the landscape of eyecare,” Loughman said.

Ocumetra’s myopia management solution is designed to offer evidence-based clinical support, the company stated. In partnering with Topcon Healthcare, the group noted that they hope to expand access to innovative digital health care solutions and empower eyecare professionals with more precise, data-driven insights and advanced tools. 

“The Ocumetra mission, their trustworthy and transparent leadership team, and their scientifically backed solution are well aligned with Topcon Healthcare’s mission to deliver evidence-based clinical decision support solutions that address the most imminent clinical needs, globally,” added Ali Tafreshi, CEO and president of Topcon Healthcare, Inc. “Our investment and strategic collaboration aim to accelerate Ocumetra’s goal to implement and scale their solutions quickly and cost-effectively, just in time to align with available and upcoming therapies for myopia.”